EXEL Stock - Exelixis, Inc.
Unlock GoAI Insights for EXEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.17B | $1.83B | $1.61B | $1.43B | $987.54M |
| Gross Profit | $2.09B | $1.76B | $1.55B | $1.38B | $951.27M |
| Gross Margin | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% |
| Operating Income | $604.62M | $170.88M | $201.48M | $286.67M | $110.06M |
| Net Income | $521.27M | $207.76M | $182.28M | $231.06M | $111.78M |
| Net Margin | 24.0% | 11.4% | 11.3% | 16.1% | 11.3% |
| EPS | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| November 3rd 2025 | Guggenheim | Downgrade | Neutral | - |
| October 21st 2025 | Leerink Partners | Upgrade | Outperform | $48 |
| September 19th 2025 | Barclays | Resumed | Equal Weight | $40 |
| September 17th 2025 | Barclays | Resumed | Equal Weight | $40 |
| September 17th 2025 | Goldman | Initiation | Buy | $47 |
| July 8th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $50← $45 |
| June 24th 2025 | Stephens | Upgrade | Overweight | $60 |
| February 24th 2025 | Wells Fargo | Downgrade | Equal Weight | $36 |
| January 27th 2025 | Morgan Stanley | Upgrade | Overweight | $40← $30 |
| January 24th 2025 | Oppenheimer | Downgrade | Perform | - |
| December 20th 2024 | BMO Capital Markets | Downgrade | Market Perform | $40← $36 |
| December 17th 2024 | BofA Securities | Downgrade | Neutral | $39← $35 |
| October 16th 2024 | RBC Capital Mkts | Reiterated | Outperform | $34← $30 |
| September 19th 2024 | UBS | Initiation | Neutral | $30 |
Earnings History & Surprises
EXELEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 10, 2026 | $0.74 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.69 | $0.78 | +13.9% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $0.65 | $0.75 | +15.4% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $0.36 | $0.62 | +73.1% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.51 | $0.55 | +7.8% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.35 | $0.40 | +14.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.30 | $0.77 | +156.7% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $0.28 | $0.17 | -39.3% | ✗ MISS |
Q1 2024 | Feb 6, 2024 | $0.21 | $0.27 | +28.6% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.10 | $0.10 | 0.0% | = MET |
Q3 2023 | Aug 1, 2023 | $0.16 | $0.25 | +56.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.15 | $0.12 | -20.0% | ✗ MISS |
Q1 2023 | Feb 7, 2023 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $0.19 | $0.23 | +21.1% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.19 | $0.22 | +15.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.14 | $0.21 | +50.0% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $0.06 | $0.29 | +383.3% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $0.17 | $0.12 | -29.4% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $0.06 | $0.30 | +400.0% | ✓ BEAT |
Q2 2021 | May 6, 2021 | — | $0.00 | — | — |
Latest News
UBS Maintains Neutral on Exelixis, Raises Price Target to $40
➖ NeutralTD Cowen Maintains Buy on Exelixis, Raises Price Target to $51
📈 PositiveMorgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $45
📈 PositiveBarclays Maintains Equal-Weight on Exelixis, Raises Price Target to $41
📈 PositiveHC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $49
📈 PositiveExelixis Authorizes $750M Stock Repurchase By 2026
📈 PositiveExelixis Non-GAAP EPS of $0.78 beats by $0.11, revenue of $597.8M beats by $8.05M
📈 PositiveExelixis Raises FY2025 Sales Guidance from $2.250B-$2.350B to $2.300B-$2.350B vs $2.320B Est
📈 PositiveExelixis Q3 Adj. EPS $0.78 Beats $0.61 Estimate, Sales $597.755M Beat $589.770M Estimate
📈 PositiveGuggenheim Downgrades Exelixis to Neutral
📉 NegativeMorgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
➖ NeutralRBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target
➖ NeutralWells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30
➖ NeutralLeerink Partners Upgrades Exelixis to Outperform, Announces $48 Price Target
📈 PositiveExelixis shares are trading lower. The company announced results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with previously treated non-microsatellite instability-high metastatic colorectal cancer.
📉 NegativeReported Saturday, Exelixis Highlights 81% Reduction In Disease Progression Or Death With CABOMETYX In Advanced Lung And Thymic NET; Median Progression-Free Survival Reached 8.2 Months Vs. 2.7 Months For Placebo
📈 PositiveExelixis Phase 3 STELLAR-303: Zanzalintinib Plus Atezolizumab Extends Survival To 10.9 Months In Metastatic Colorectal Cancer
📈 PositiveExelixis shares are trading higher after Morgan Stanley maintained it Overweight rating on the stock and raised its price target to $50. Goldman Sachs also initiated coverage on the stock with a BUY rating and price target of $47
📈 PositiveMorgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $50
📈 PositiveGoldman Sachs Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $47
📈 PositiveFrequently Asked Questions about EXEL
What is EXEL's current stock price?
What is the analyst price target for EXEL?
What sector is Exelixis, Inc. in?
What is EXEL's market cap?
Does EXEL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EXEL for comparison